Skip to main content

Oncology Data Advisor at ASH

Oncology Data Advisor® · Racial and Socioeconomic Disparities in the CLL Community Oncology Setting: Ira Zackon, MD At the recent 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Ira Zackon, MD, a Senior Medical Director with Ontada, to discuss his abstract and presentation about racial and socioeconomic disparities experienced by patients in the chronic lymphocytic leukemia (CLL) community oncology and hematology setting, how to comba...
Oncology Data Advisor® · Investigating Odronextamab for R/R FL and DLBCL in the ELM-2 Study: Sabarish Ayyappan, MD At the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Sabarish Ayyappan, MD, the Director of Hematological Malignancies at the City of Hope Cancer Center, to discuss the ELM-2 study which investigated odronextamab for relapsed/refractory (R/R) follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).   Oncology...
Oncology Data Advisor® · Utilizing ctDNA to Assess Survival With Odronextamab for FL and DLBCL: Jon Arnason, MD At the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Jon Arnason, MD, a Lymphoma Clinical Trial Specialist at Beth Israel Deaconess Medical Center, to discuss his abstract and presentation regarding the ELM-2 trial which studied circulating tumor DNA (ctDNA) as a predictive biomarker with odronextamab for follicular lymphoma (F...
Oncology Data Advisor® · Guiding Dietary Choices During Multiple Myeloma Treatment: Richa Parikh, MD In this interview from the 2023 American Society of Hematology Annual Meeting, Richa Parikh, MD, a third-year Hematology/Oncology Fellow at Karmanos Cancer Institute, discusses her team's study investigating the role of diet in multiple myeloma and how its findings can be used to help guide dietary decisions for patients.  ...
Oncology Data Advisor® · Highlights of Multiple Myeloma Research Presented at ASH 2023: Urvi Shah, MD At the recent American Society of Hematology (ASH) Annual Meeting, numerous updates were presented with the potential to impact practice in relapsed/refractory multiple myeloma. While at the meeting, Urvi Shah, MD, Assistant Attending in the Myeloma Service at Memorial Sloan Kettering Cancer Center, shares some of most significant highlights of the clinical trials and therapeutic agen...
Oncology Data Advisor® · Real-World Outcomes of Brexucabtagene Autoleucel for Mantle Cell Lymphoma: Swetha Kambhampati, MD At the recent American Society of Hematology (ASH) Annual Meeting, Swetha Kambhampati, an Assistant Professor in the Division of Lymphoma at City of Hope, sat down with Oncology Data Advisor to further discuss her presentationregarding real-world outcomes of brexucabtagene autoleucel (brexu-cel) in patients with relapsed/refractory mantle cell lymphoma.   Onc...
Oncology Data Advisor® · Exploring Revumenib for KMT2-Rearranged Acute Leukemias in the AUGMENT Trial: Ibrahim Aldoss, MD Recently, at the American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Ibrahim Aldoss, MD, an Associate Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, to further discuss his presentation investigating revumenib for patients with relapsed/refractory histone-lysine N-methyltransfera...
Oncology Data Advisor® · Managing Acute Leukemias and Lymphomas When Patients Stay Local: Dipti Patel-Donnelly, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Dipti Patel-Donnelly, a Medical Oncology at Virginia Cancer Specialists, hosted a session highlighting how to optimize management when patients with hematologic malignancies stay local. In this podcast episode, Dr. Patel-Donnelly sits down with Oncology Data Advisor to discuss her session, share some o...
Oncology Data Advisor® · Exploring Acalabrutinib ± Obinutuzumab for CLL in the ELEVATE-TN Study: Jeff Sharman, MD Recently, at the American Society of Hematology (ASH) Annual Meeting, Dr. Jeff P. Sharman, the Medical Director of Hematology Research for Sarah Cannon Research Institute and the US Oncology Network, presented the long-term follow up results from the ELEVATE-TN study, which investigated acalabrutinib plus or minus obinutuzumab for previously untreated patients with ...
Oncology Data Advisor® · Improving End-of-Life Care for Patients With AML Receiving Non-Curative Therapy: Richa Thakur, MD In this interview from the American Society of Hematology (ASH) Annual Meeting, Dr. Richa Thakur, OncData Fellows Forum member and Hematology/Oncology Fellow at Northwell Health, discusses her poster presentation on end-of-life outcomes in patients with acute myeloid leukemia (AML) receiving non-curative chemotherapy. Dr. Thakur shares her passion for improving pa...
Oncology Data Advisor® · Improving QOL in Multiple Myeloma With Bortezomib Dose Reduction: Rahul Banerjee and Gurbakhash Kaur At the 2023 American Society of Hematology (ASH) Annual Meeting, Dr. Rahul Banerjee, Editor in Chief of Oncology Data Advisor, sat down with Dr. Gurbakhash Kaur, an Assistant Professor of Medicine at the University of Texas (UT) Southwestern Medical Center, to discuss their abstract about real-world dosing and prescribing patterns of bortezomib in newly diagnos...
Oncology Data Advisor® · Real-World Outcomes of Brexuctabtagene Autoleucel for B-Cell ALL: Evandro Bezerra, MD Recently, at the American Society of Hematology (ASH) Annual Meeting, Dr. Evandro Bezerra, a Hematology Specialist at the Ohio State University Comprehensive Cancer Center, sat down with Oncology Data Advisor to discuss his team's research regarding real-world outcomes of brexucabtagene autoleucel (brexu-cel) for B-cell acute lymphoblastic leukemia (ALL).   Oncology Data...
Oncology Data Advisor® · Investigating Therapies Targeting Cardiovascular Health in MDS: Diego Adrianzen Herrera, MD In this interview from the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor speaks with Dr. Diego Adrianzen Herrera, a Malignant Hematologist at the University of Vermont Medical Center, about his study investigating the impact of hypomethylating agents on cardiovascular disease risk for patients with myelodysplastic syndromes (MDS). Dr. A...
Oncology Data Advisor® · Investigating Talquetamab + Pomalidomide in the MonumenTAL-2 Study: Jeffrey Matous, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Jeffrey Matous, MD, a Member of the Colorado Blood Cancer Institute in Denver, Colorado, presented his team's research and results of the MonumenTAL-2 trial, which studied talquetamab plus pomalidomide in patients with relapsed/refractory multiple myeloma. Dr. Matous then sat down with Oncology Data Advis...
Oncology Data Advisor® · Improving Diversity in Multiple Myeloma Clinical Trials: Craig Cole, MD At the recent American Society of Hematology (ASH) Annual Meeting, Craig Cole, MD, Assistant Professor at Karmanos Cancer Institute, sat down with Oncology Data Advisor to share his passion for improving diversity in multiple myeloma clinical trials. He discusses the efforts that are currently underway to increase diverse accrual and the importance of raising awareness in order to address ...
Oncology Data Advisor® · Empowering Patients Through Shared Decision Making in Myelodysplastic Syndromes: Claire Saxton At the 2023 American Society of Hematology (ASH) Annual Meeting, Claire Saxton, Executive Vice President of Insights and Impact at Cancer Support Community, presented her team's study on communication that enables shared decision making in myelodysplastic syndromes (MDS). While there, she sat down with Oncology Data Advisor to discuss more about the results of the st...
Oncology Data Advisor® · Mitigating the Effects of Neighborhood Disadvantage in Acute Myeloid Leukemia: Brittany Ragon, MD   At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Brittany Ragon, Adult Leukemia and Transplant Specialist at Levine Cancer Institute, sat down with Oncology Data Advisor to discuss her presentation on neighborhood disadvantages associated with inferior overall survival outcomes for patients with acute myeloid leukemia (AML). In additio...
Oncology Data Advisor® · Response Patterns of Linvoseltamab for Relapsed/Refractory Multiple Myeloma: Hans Lee, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Hans Lee, the Director of Multiple Myeloma Clinical Research at MD Anderson, presented his team's research from the LINKER-MM1 study, which sought to evaluate response patterns of linvoseltamab for relapsed/refractory multiple myeloma. Later, Dr. Lee sat down with Oncology Data Advisor to further discu...
Oncology Data Advisor® · CLL Society: Paving the Way For CLL Patients and Survivors With Brian Koffman, MD CLL Society is a patient-centric, physician-curated nonprofit organization that prioritizes patient education, advocacy, and research for the chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) community. Dr. Brian Koffman co-founded the organization after being diagnosed with CLL in 2005, and he currently serves as Executive Vice President and Chief Medical O...
Oncology Data Advisor® · Patterns of Care With BTK Inhibitors for CLL/SLL in the Community Setting: David Andorsky, MD At the recent American Society of Hematology (ASH) Annual Meeting in San Diego, Dr. David Andorsky, MD, a Clinical Hematologist and Medical Oncologist at the Rocky Mountain Cancer Centers in Boulder, Colorado, presented his research and observations regarding patterns of care with Bruton tyrosine kinase (BTK) inhibitors and the distribution of social determinants of h...
Oncology Data Advisor® · A Mobile App to Address Sexual Dysfunction in HSCT Survivors: Areej El-Jawahri, MD After receiving hematopoietic stem cell transplantation (HSCT), many survivors experience issues with sexual dysfunction which can impact their quality of life. To address this challenge, Dr. Areej El-Jawahri, Director of the Bone Marrow Transplant Survivorship Program at Massachusetts General Hospital (MGH), and her team developed a multimodal mobile app as an intervention for ...
Oncology Data Advisor® · Exploring Results of the IsKia Trial in Newly Diagnosed Multiple Myeloma: Annemiek Broijl, MD In this interview from the 2023 American Society of Hematology (ASH) Annual Meeting, Dr. Annemiek Broijl, Hematologist at Erasmus MC Cancer Institute in the Netherlands, discusses the IsKia trial, of which she is the Co-Primary Investigator, and its unique primary end point of measurable residual disease (MRD).  ...
Oncology Data Advisor® · Financial Hardship Experienced During Transplant in Myelodysplastic Syndromes: Christopher Su, MD At the recent American Society of Hematology (ASH) Annual Meeting in San Diego, Christopher Su, MD, a Hematologist at the Fred Hutchinson Cancer Center, presented his research regarding financial hardships experienced in the transplant setting for myelodysplastic syndromes (MDS). Dr. Su then set down with Oncology Data Advisor to further discuss his study, the res...
Oncology Data Advisor® · Coping With Psychological Distress Prior to Hematopoietic Cell Transplantation: Richard Newcomb, MD Patients with hematologic malignancies undergoing hospitalization for hematopoietic cell transplantation experience significant psychological distress, and they cope in different ways. In this interview from the 2023 American Society of Hematology (ASH), Dr. Richard Newcomb, Instructor of Medicine at Harvard Medical School, discusses his presentation on coping m...
Oncology Data Advisor® · Evaluating Outpatient Teclistamab Administration in Multiple Myeloma: Robert Rifkin, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Robert Rifkin, MD, FACP, a Board-Certified Medical Oncologist and Hematologist at the Rocky Mountain Cancer Centers in Denver, Colorado, sat down with Oncology Data Advisor to discuss his study and presentation on the OPTEC trial, in which administration of the bispecific antibody teclistamab will be eva...
Oncology Data Advisor® · Advancing Inclusion for Blood Donation Systems for Marginalized Groups: Warren Fingrut, MD At the recent American Society of Hematology (ASH) Annual Meeting, Warren Fingrut, MD, a Transplant and Cell Therapy Physician at MD Anderson Cancer Center and Founder and Director of Stem Cell Club, a donor recruitment organization based in Canada, sat down with Oncology Data Advisor to discuss his team's research and presentation addressing disparities experienced by m...
Oncology Data Advisor® · Nurse Navigation to Address Socioeconomic Disparities in ALL Treatment: Greg Knight, MD In this interview from the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor speaks with Greg Knight, MD, Clinical Assistant Professor of Medicine at Levine Cancer Institute, about his presentation on the impacts of nurse navigation and other supportive care services for reducing socioeconomic disparities in acute lymphoblastic leukemia (ALL) t...
Oncology Data Advisor® · Maintaining Functioning and QOL With Odronextamab for Follicular Lymphoma: Benoit Tessoulin, MD At the recent American Society of Hematology (ASH) Annual Meeting, Benoit Tessoulin, MD, PhD, Head of the Lymphoma Department at the Nantes University Hospital in France, sat down with Oncology Data Advisor to discuss the results from the ELM-2 study in which the efficacy of odronextamab was investigated for maintaining functionality and quality of life in patients ...
Oncology Data Advisor® · Investigating Hypomethylating Agents for Myelodysplastic Syndromes With Amer Zeidan Recently, at the American Society of Hematology (ASH) Annual Meeting, Amer Zeidan, MBBS, MHS, the Interim Chief of Hematologic Malignancies Division at the Yale Cancer Center, presented his abstract regarding an investigation of oral decitabine and cedazuridine versus intravenous/subcutaneous hypomethylating agents (HMA) for patients with myelodysplastic syndromes (MDS). In thi...
Oncology Data Advisor® · Lowering Talquetamab Dosing Intensity to Improve Tolerability: Ajai Chari, MD At the recent American Society of Hematology (ASH) Annual Meeting, Ajai Chari, MD, Director of the Myeloma Program at the University of California, San Francisco, sat down with Oncology Data Advisor to discuss his abstract and presentation regarding updated results from the MonumenTAL-1 study and what to look forward to from the ever-evolving treatment landscape of multiple myeloma. ...
Recently, at the American Society of Hematology (ASH) Annual Meeting, Amer Zeidan, MBBS, MHS, the Interim Chief of Hematologic Malignancies Division at the Yale Cancer Center, presented his abstract regarding an investigation of oral decitabine and cedazuridine versus intravenous/subcutaneous hypomethylating agents (HMA) for patients with myelodysplastic syndromes (MDS). In this interview, Dr. Zeidan further delves into his research and what it could mean for the future treatment landscape of MD...
Oncology Data Advisor® · Addressing Ethical Concerns Around Artificial Intelligence in Cancer Care: Andrew Hantel, MD In this interview from the 2023 American Society of Hematology (ASH) Annual Meeting, Dr. Andrew Hantel, Instructor in Medicine at Harvard Medical School, shares more about his presentation on oncologists' perspectives on ethical implications of artificial intelligence (AI) in cancer care, as well as ongoing efforts build a framework for the integration of AI into oncol...
Oncology Data Advisor® · Investigating CD19-Targeted CAR T Cells for Autoimmune Diseases: Fabian Mueller, MD In this interview from the American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor speaks with Fabian Mueller, the Principal Investigator at the Laboratory of Molecular Immunotherapeutics (LMIT) at the University Hospital of Erlangen, in Germany, about his study which investigated CD19-targeted CAR T cells for refractory systemic autoimmune diseases.   O...
Oncology Data Advisor® · Expanding Access to Brexucabtagene Autoleucel for Mantle Cell Lymphoma: Andre Goy, MD In this interview from the American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor speaks with Dr. Andre Goy, Chair of the John Theurer Cancer Center and Hackensack University Medical Center, about his presentation on an expanded access study of brexucabtagene autoleucel (brexu-cel) for patients with mantle cell lymphoma who were ineligible for the ZUMA-2 a...
Oncology Data Advisor® · Reducing Stigmatizing Language in the EMR for More Equitable Care: Alex Boucher, MD In this interview from the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor speaks with Dr. Alex Boucher, Director of the Pediatric and Adult Sickle Cell Programs at the University of Minnesota Medical School, about his presentation on racial discrepancies in the use of stigmatizing language in hematology/oncology electronic medical records. Dr. B...
Oncology Data Advisor® · Harnessing Machine Learning for MCL Risk Prognostication With Adrian Mosquera, MD, PhD In this interview from the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor speaks with Dr. Adrian Mosquera Orguiera, Clinical Hematologist at the University Hospital of Santiago de Compostela, about his research team's novel machine learning model that incorporates patient characteristics and histological subtype into risk prognostication for ...
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. This podcast series features exclusive conversations on breaking data for novel therapies, technological innovations in hematology/oncology, efforts to reduce disparities and improve health equity, and more! Part 3 Oncology Data Advisor® · Onc...
Oncology Data Advisor™ · Investigating Brentuximab Vedotin for Advanced-Stage Hodgkin Lymphoma With Habte Yimer, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Habte Yimer of Texas Oncology sat down with Oncology Data Advisor to elaborate on the promising results of brentuximab vedotin for patients with advanced-stage classical Hodgkin lymphoma, including the most recent data and future directions for the trial.  ...
Oncology Data Advisor™ · Investigating Momelotinib for Treatment of Myelofibrosis With Srdan Verstovsek, MD, PhD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Srdan Verstovsek, Chief of the Section for Myeloproliferative Neoplasms in the Department of Leukemia at MD Anderson Cancer Center, sat down to discuss his presentation on the results of research regarding momelotinib in treatment of myelofibrosis. This podcast episode was recorded live by Oncology Dat...
Oncology Data Advisor™ · Describing Real-World Treatment Patterns for Myelodysplastic Syndromes With Ira Zackon, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Ira Zackon sat down with Oncology Data Advisor to discuss his abstract regarding real-world treatment patterns and survival outcomes among patients with myelodysplastic syndromes (MDS), including ways for making clinical trial data applicable for patients treated in the community oncology setting. &...
Oncology Data Advisor™ · Subsequent Treatment After CAR T-Cell Therapy in Large B-Cell Lymphoma With Armin Ghobadi, MD Recently, at the American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Armin Ghobadi, an Associate Professor at the Washington University School of Medicine, Siteman Cancer Center, sat down with Oncology Data Advisor to enlighten us about his research and presentation regarding the ZUMA-7 trial, in which he discusses the outcomes of subsequent anti...
Oncology Data Advisor™ · Optimizing Patient Outcomes With CAR T-Cell Therapy With Ola Oluwole, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Ola Oluwole of Vanderbilt University Medical Center, sat down with Oncology Data Advisor to discuss two of his abstracts on prophylactic corticosteroid use for patients receiving axicabtagene ciloleucel and the role of cytokine release syndrome in the efficacy of chimeric antigen receptor (CAR) T-cell therapy.  ...
Oncology Data Advisor™ · Improving the Standard of Care for Advanced Hodgkin Lymphoma With Mitul Gandhi, MD At the recent American Society of Hematology (ASH) Annual Meeting, updated results were presented for the SGN35-027 study of brentuximab vedotin plus nivolumab and chemotherapy for advanced-stage classical Hodgkin lymphoma. One of its authors, Dr. Mitul Gandhi of Virginia Cancer Specialists, sat down with Oncology Data Advisor while there to discuss the importance of the trial...
Oncology Data Advisor™ · Updates on Trials of Zilovertamab and Brentuximab Vedotin in Lymphomas With Hun Lee, MD At the recent American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor met with Dr. Hun Lee of MD Anderson to discuss the two abstracts that he presented there. Dr. Lee provided an update on the promising data for zilovertamab plus ibrutinib for patients with mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL)...
Oncology Data Advisor™ · Association of Socioeconomic Status With Adherence and Survival in Myeloma: Leon Bernal-Mizrachi, MD At the recent American Society of Hematology (ASH) Annual Meeting in New Orleans, Leon Bernal-Mizrachi, MD, an Associate Professor of Medicine in the Department of Hematology and Oncology at the Emory University School of Medicine, sat down with Oncology Data Advisor to discuss his research and presentation regarding association of socioeconomic status with a...
Oncology Data Advisor™ · Advancing the Careers of Women in Hematology With Ariela Marshall, MD At the recent American Society of Hematology (ASH) Annual Meeting, Ariela Marshall, MD, Director of the Women's Hemostasis and Thrombosis Program and Associate Professor of Clinical Medicine at Penn Medicine, sat down with Oncology Data Advisor to talk about the ASH Women in Hematology Working Group, a group committed to career advances and leadership opportunities for women in hematology....
Oncology Data Advisor™ · Factors Leading to Black Patient Disparities in Hematology Trials With Shakira Grant, MBBS At the recent American Society of Hematology (ASH) Annual Meeting, Shakira J. Grant, MBBS, an Assistant Professor of Medicine at the University of North Carolina at Chapel Hill, sat down with Oncology Data Advisor to discuss her research she presented, "If You Don't Trust Your Doctor That Much…You'd Feel Less Confident Doing a Research Study": Factors Influencing Black...
Oncology Data Advisor™ · Making Health Care Accessible for Acute Myeloid Leukemia Patients With Ian Bouligny, MD At the 2022 American Society of Hematology (ASH) Annual Meeting, Dr. Ian Bouligny, Hematology/Oncology Fellow at Virginia Commonwealth University (VCU) Massey Cancer Center, spoke with Oncology Data Advisor about his abstract regarding health care disparities faced by Black patients with acute myeloid leukemia (AML). Dr. Bouligny explains the factors that contribute to tr...
Oncology Data Advisor™ · Creating Valuable Education for the Hematology/Oncology Fellow: Ronak Mistry and Vivek Patel At the 2022 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Dr. Ronak Mistry and Dr. Vivek Patel, Clinical Fellows in Medicine at Vanderbilt University and hosts of The Fellow on Call podcast. Dr. Mistry and Dr. Patel share their passion for creating education geared towards fellows and the valuable experience of attending ASH...
Oncology Data Advisor™ · Dynamic Risk Classification of Smoldering Myeloma With Luis Gerardo Rodríguez-Lobato, MD, PhD At the recent American Society of Hematology (ASH) Annual Meeting, Luis Gerardo Rodríguez-Lobato, MD, PhD, Specialist in Hematopoietic Stem Cell Transplant and Researcher at the Hospital Clínic de Barcelona and barnaclínic+, sat down with Oncology Data Advisor to discuss his research regarding dynamic risk classification for patients with smoldering multiple ...
Oncology Data Advisor™ · Understanding Multiple Myeloma Treatment Patterns and Sequencing With Robert Rifkin, MD At the recent 64th American Society of Hematology (ASH) Annual Meeting, Dr. Robert Rifkin, Medical Oncologist and Hematologist at Rocky Mountain Cancer Centers in Denver, Colorado, sat down with Oncology Data Advisor to discuss the research that he presented, titled Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM ...
Oncology Data Advisor™ · Exploring the Results of Elranatamab for Relapsed/Refractory Multiple Myeloma With Noopur Raje, MD Recently, Dr. Noopur Raje, Director of the Center for Multiple Myeloma at Massachusetts General Hospital, sat down with Oncology Data Advisor at the 64th American Society of Hematology (ASH) Annual Meeting to discuss the results of the MagnetisMM-1 study of elranatamab for multiple myeloma that she presented. Dr. Raje elaborates on the efficacy and safety of th...
Oncology Data Advisor™ · Investigating CAR T Wait Time and High-Risk Myeloma Definitions With Samer Al Hadidi, MD, MS, FACP At the recent 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Samer Al Hadidi, Assistant Professor at the University of Arkansas, sat down with Oncology Data Advisor to discuss the multiple myeloma research that he presented. Dr. Al Hadidi elaborates on his studies regarding the wait list for patients who are eligible to receive chi...
Oncology Data Advisor™ · Studying the Promising Role of Bispecific Antibodies in Multiple Myeloma With Ajai Chari, MD At the recent American Society of Hematology (ASH) Annual Meeting, Ajai Chari, MD, the Director of Research in the Multiple Myeloma Program at the Icahn School of Medicine at Mount Sinai, New York, sat down with Oncology Data Advisor to discuss his presentation regarding the phase 1/2 results of the MonumenTAL-1 study. This study researches the possible benefit of ta...
Oncology Data Advisor™ · Investigating the Efficacy of HPN217 in Relapsed/Refractory Multiple Myeloma With Luke Walker, MD At the recent 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Luke Walker, Chief Medical Officer of Harpoon Therapeutics, sat down with Oncology Data Advisor to discuss the results of a phase 1 trial of HPN217, a B-cell maturation antigen (BCMA)–targeting T-cell engager, which were presented at the meeting. Dr. Walker delves into the...
Oncology Data Advisor™ · Discussing the Relevance of Urine Studies in Myeloma With Kelsey Natsuhara, MD At the recent American Society of Hematology (ASH) Annual Meeting, Kelsey Natsuhara, MD, a Fellow in Hematology and Oncology at the University of California, San Francisco, sat down with Oncology Data Advisor and ConveyMED to discuss her presentation regarding the relevance of urine studies in myeloma patients undergoing transplantation. This podcast episode was recorded live by O...
Oncology Data Advisor™ · ASH 2022 Conversations on Multiple Myeloma (Part 1) With Manni Mohyuddin, MBBS At the recent 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Manni Mohyuddin, Assistant Professor at the University of Utah Huntsman Cancer Institute, sat down with Oncology Data Advisor to discuss the multiple myeloma research he was involved with at this year's meeting. Dr. Mohyuddin elaborates on his abstracts regarding the prognostic value of (11;...
Oncology Data Advisor™ · Pioneering the Field of Stem Cell Biology With Irving Weissman, MD At the recent American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Irving Weissman, Director of the Institute of Stem Cell Biology and Regenerative Medicine at Stanford University, received the 2022 Wallace H. Coulter Award for Lifetime Achievement in Hematology. In this interview, Dr. Weissman tells the story of how he entered the field, describes the monumental contributi...
At the recent American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Irving Weissman, Director of the Institute of Stem Cell Biology and Regenerative Medicine at Stanford University, received the 2022 Wallace H. Coulter Award for Lifetime Achievement in Hematology. In this interview, Dr. Weissman tells the story of how he entered the field, describes the monumental contributions he has made in hematology and oncology, and shares advice for medical students who are interested in ...
Tumor suppressor gene p53 is the most frequently mutated gene in human malignancy. Through a complex series of molecular events, p53 leads to malignant cell proliferation and plays a significant role in tumor formation. In the Presidential Symposium at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia, Dr. Matthew Davids of Harvard Medical School discussed the current therapeutic strategies used to inhibit or reactivate mutant p53 in the treatment ...
Although survival in childhood acute lymphoblastic leukemia (ALL) has improved over the years, there remains a need to identify racial, ethnic, and socioeconomic health disparities that contribute to poor outcomes. In a study recently presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, a team of researchers led by Dr. Sumit Gupta of the University of Toronto investigated the impact of race, ethnicity, and socioeconomic status among young patients with ALL ...
For patients with extensive-stage small cell lung cancer (SCLC), cytotoxic chemotherapy remains a mainstay of treatment. However, myelosuppressive hematologic adverse events such as anemia, neutropenia, and thrombocytopenia pose a significant challenge to care. In a study recently presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia, a team of researchers led by Dr. Jerome Goldschmidt, medical oncologist at Blue Ridge Cancer Care and the ...
For patients with relapsed/refractory large B-cell lymphoma (LBCL), treatment options are limited, and outcomes remain poor with the current standard of care. In the phase 3 TRANSFORM trial, Dr. Manali Kamdar, Clinical Director of Lymphoma Services at the University of Colorado Anschutz School of Medicine, and colleagues investigated the efficacy of lisocabtagene maraleucel (liso-cel), an anti-CD19–directed chimeric antigen receptor (CAR) T-cell therapy, in this setting. Dr. Kamdar recently pres...
Compared with the non-Hispanic White population, Hispanic and Black adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) experience significantly inferior outcomes. In an analysis of the CALGB 10403 AYA trial presented at the recent American Society of Hematology (ASH) 63rd Annual Meeting & Exposition in Atlanta, Georgia, a team of researchers led by Dr. Lori Muffly, Associate Professor of Medicine at Stanford University, investigated racial and ethnic disparities in cl...
One of the issues surrounding hematology care is the underrepresentation of racial and ethnic minorities in clinical trials. At the recent 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia, Alexis A. Thompson, MD, MPH, past President of ASH and Professor of Pediatrics at Northwestern University's Feinberg School of Medicine, shared her thoughts on strategies for remedying these disparities so that more inclusive care can be provided for patients with h...
While the current standard of care for relapsed/refractory large B-cell lymphoma is high-dose therapy with autologous stem cell rescue, many patients do not respond to or cannot tolerate high-dose therapy. As a result, outcomes for second-line treatment remain poor. At the recent American Society of Hematology (ASH) 63rd Annual Meeting & Exposition in Atlanta, Georgia, Dr. Frederick Locke of Moffitt Cancer Center presented the primary results of ZUMA-7, a phase 3 clinical trial investigating...
For patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), less than half of patients are cured with the current standard of care, and effective treatments are greatly needed. In the phase 3 POLARIX trial, a team of researchers investigated the efficacy of polatuzumab vedotin in combination with R-CHP (rituximab/cyclophosphamide/doxorubicin/prednisone) for this population. In this interview, one of the study's investigators, Dr. John Burke of Rocky Mountain Cancer Centers and the U...
For patients with relapsed/refractory T-cell lymphoma (TCL), standard therapies provide an overall response rate of only 25% to 35%, and novel therapeutic options are greatly needed. In a study recently presented at the American Society of Hematology (ASH) 63rd Annual Meeting & Exposition in Atlanta, Georgia, a team of researchers led by Dr. Steven M. Horwitz, medical oncologist at Memorial Sloan Kettering Cancer Center, investigated the efficacy of the phosphoinositide-3-kinase inhibitor du...
For older patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML) with 20% to 30% marrow blasts, treatment options are limited. In the PANTHER study, the results of which were recently presented at the American Society of Hematology (ASH) 63rd Annual Meeting & Exposition in Atlanta, Georgia, a team of researchers led by Dr. Mikkael A. Sekeres, Professor of Medicine and Chief of the Division of Hematology at the Univer...
Understanding the balance between effective treatments and health-related quality of life is crucial, especially when treating older adults with hematologic malignancies. The Cancer and Aging Research Group (CARG) chemotherapy toxicity calculator has been sufficiently studied and utilized in patients with solid tumors; however, its efficacy in the hematologic malignancy setting was previously unknown. In a study recently presented at the American Society of Hematology (ASH) 63rd Annual Meeting &...
While chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment landscape for patients with hematologic malignancies, challenges remain in the management of short-term toxicities, most notably cytokine release syndrome and neurologic symptoms. In nearly all cases to date, optimal management has only been achieved through inpatient admission for frequent monitoring; however, an onsite hospital stay can create a significant burden for the patient. As part of a study recent...
i3 Health's study focusing on the effectiveness of an online continuing medical education (CME)/nursing continuing professional development (NCPD)–approved activity to improve clinicians' knowledge of therapeutic advances in T-cell lymphoma (TCL) has been published as a 63rd American Society of Hematology (ASH) Annual Meeting & Exposition online abstract. ...